key: cord-0046086-7juumedy
authors: nan
title: Full Issue PDF
date: 2020-06-22
journal: JACC Basic Transl Sci
DOI: 10.1016/s2452-302x(20)30243-6
sha: 6780cb174d08c4ca204b4e13653358ae4cb3722a
doc_id: 46086
cord_uid: 7juumedy

nan

. In contrast, the PCSK9 inhibitor alirocumab was shown to increase (albeit not significantly) the FCR of Lp(a) in 1 study (12) , whereas the PCSK9 inhibitor evolocumab in monotherapy did not alter Lp(a) FCR. However, combined with a statin, evolocumab did increase Lp(a) FCR in that study (13) .

We have recently reported that alirocumab does not significantly modulate Lp(a) FCR in nonhuman primates (14) . Therefore, the role of LDLR in mediating Lp(a) plasma clearance remains a matter of considerable debate.

Lp(a) is only found in humans, old-world monkeys, and hedgehogs. None of the common animal models naturally presents the Lp(a) trait, which severely complicates functional in vivo analysis (2) . Using an original mouse model repopulated with human hepatocytes (15) combined with transillumination tomography imaging techniques as well as primary human lymphocytes (16, 17) and flow cytometry to track fluorescent lipoproteins, we provide new evidence that LDLR is not a significant contributor to Lp(a) clearance ex vivo and in vivo. Lp(a)-bodipy was maintained during uptake experiments, Lp(a) diluted in culture medium before and after incubation with primary PBMCs was subjected to Western blot analysis for apoB100 under reducing and nonreducing conditions using the AF3260 antihuman apoB100 antibody (Bio-Techne, Rennes, France), as described previously (9, 19) . Table 1 ) by LC-MS/MS (14) . The limit of detection of this assay is 1 nmol/l. Serum lipoproteins were resolved using a fast performance liquid chromatography Äkta system (GE Healthcare) and

cholesterol measured in the eluted fractions using the Amplex Red Cholesterol Assay Kit (Life Technologies) (14) . Serum samples were analyzed for direct LDL-C on a Pentra 400 biochemical analyzer (Horiba ABX, Montpellier, France) using standard colorimetric assays, for apo(a) using the STA-359 ELISA kit (Cell Biolabs) with a limit of detection of 0.1 pmol/l, and for human apoB100 using the EA7001-1 ELISA kit (Assaypro, Saint-Charles Missouri). The total PCSK9

concentrations were determined using the Quantikine SPC900 ELISA (R&D Systems). In line with these observations, we next investigated the relationship between LDLR and Lp(a) by correlating LDLR cell surface expression measured in Western blot analysis (data not shown). These animals also express human apoB100 and human PCSK9 in their plasma. We determined that 72% of their total apoB100 was human and 28% murine, indicating a degree of hepatic chimerism close to 80% because a small amount of apoB100 can derive from the intestine in rodents (21) . We next ascertained that FRG mice responded to alirocumab. Compared with controls, alirocumab reduced LDL-C levels (1.86 AE However, the present results remain at odds with studies conducted in mouse primary hepatocytes, human skin fibroblasts, and cell lines by others (6, 8) .

There is certainly an inherent limitation of using primary lymphocytes as a proxy for hepatocytes, but this cell type is easily accessible, and the LDLR pathway in lymphocytes and hepatocytes is similar in that it requires the same endocytic machinery, in particular the LDLR adaptor protein 1 (17) . Further advocating against a significant role for LDLR in mediating Lp(a)

clearance is the absence of significant correlation between the levels of LDLR measured at the surface of lymphocytes and the levels of circulating Lp(a), an observation that we have also made in FH patients (16) .

The absence of modulation of Lp(a) cellular uptake observed here underlines that circulating Lp(a) levels are primarily regulated at the production rather than at the catabolism level (1) .

The experiments of the present study conducted in chimeric FRG mice also indicate an absence of a significant role for LDLR in mediating Lp(a) hepatic uptake. These in vivo results are inambiguous in that they provide a direct visualization of fluorescent tracer accumulation in the livers of humanized mice, unlike stable isotope studies, which despite their merits rely on mathematical modeling and thus indirectly assess Lp(a) kinetic parameters (11) (12) (13) (14) . Our results provide a demonstration of an absence of an effect of PCSK9 inhibition with alirocumab on physiological Lp(a) uptake in human hepatocytes. Indeed, these cells are engrafted in a liver environment and not coated onto plastic with a collagen matrix, a material that has been proposed to nonspecifically bind human apo(a) (8) . However, our in vivo study has the following limitations: 1) we have only tested FRG mice repopulated with human hepatocytes from a single donor; 2) these animals present with detectable but low plasma levels of Lp(a); 3) Lp(a) accumulation beyond the hepatic region was not assessed; 

Heart failure is an important, and growing, cause of morbidity and mortality. Half of patients with heart failure have preserved ejection fraction, for whom therapeutic options are limited. Here we report that cardiac bridging integrator 1 gene therapy to maintain subcellular membrane compartments within cardiomyocytes can stabilize intracellular distribution of calcium-handling machinery, preserving diastolic function in hearts stressed by chronic beta agonist stimulation and pressure overload. This study identifies that maintenance of intracellular architecture and, in particular, membrane microdomains at t-tubules, is important in the setting of sympathetic stress. Stabilization of membrane microdomains may be a pathway for future therapeutic development. Cardiac transverse tubules (t-tubule) are critical for the initiation of calcium transients and maintenance of efficient excitationcontraction (EC) coupling. Pathological t-tubule remodeling is a consequence of b-adrenergic stimulation in HF (3) (4) (5) .

Furthermore, impaired t-tubule microdomains have been implicated in HF progression (6) (7) (8) (9) . In fact, t-tubule remodeling can be the tipping point from hypertrophy to failure (10) . Normal calcium transients (11) , which require L-type calcium channels (LTCCs) to be at t-tubule microdomains, are crucial to cardiac contraction and relaxation. The t-tubule membrane scaffolding protein cardiac bridging integrator 1 (cBIN1) (12) , which facilitates LTCC trafficking (13) and clustering for dyad organization, is also under the regulation of b-adrenergic receptor (AR) signaling (14) .

Furthermore, cBIN1 is reduced in HF (14) (15) (16) and the resultant cBIN1-microdomain disruption impairs normal stress response, limiting contractility and promoting arrhythmias. Therapeutic approaches that preserve cBIN1-microdomains may benefit stressed hearts by protecting the calcium-handling machinery, slowing HF progression.

In the present study, we explored whether in vivo over-expression of exogenous cBIN1 can limit myocardial remodeling and dysfunction. Continuous isoproterenol infusion, which causes reduced myocardial cBIN1 expression and disorganized intracellular distribution of calcium-handling proteins, also induces pathological concentric hypertrophy with diastolic dysfunction. We find that normalization of cBIN1 through adeno-associated virus 9 (AAV9) mediated gene transfer both increases inotropy and preserves lusitropy, reducing pathological hypertrophy. The cytomegalovirus (CMV) promoter was used given its efficiency and safety in cardiac gene transfer (19) . Echocardiograms were recorded using a Vevo-3100 ultrasound system (Visual Sonics, Toronto, Ontario, Canada) equipped with a 70-MHz transducer. Protein interaction was analyzed using immunofluorescent imaging and biochemical coimmunoprecipitation. Peak intensity of Cav1.2 at t-tubules is quantified using Image J as previously reported (13) . Power spectrum analysis was analyzed in Matlab using fast Fourier transform conversion (10, 13) . Intracellular protein distribution was analyzed using sucrose gradient fractionation using a previously established method (21) . For calcium transient measurement, Cal-520-AM (AAT Bioquest, Sunnyvale, California) was used as previously described (14) . Three-dimensional super-resolution stochastic optical reconstruction microscopy (STORM) images were obtained (14) for nearest neighbor analysis between LTCC-ryanodine receptor 2 (RyR) and SERCA2a-cBIN1 molecules. Figure 2B ). Live-cell imaging followed by power spectrum analysis indicates that overall t-tubule organization (normalized peak power density) remains similar in GFPþISO mice, and is increased by AAV9-cBIN1. Even though the gross t-tubule network remains organized, using transmission electron microscopy imaging, we noted in GFPþISO hearts that there was a reduction in t-tubule microfolds, which were preserved in cBIN1þISO hearts ( Figure 2C ). Quantitation of the degree of contoured t-tubules using a modified scoring system established previously (12) (1, round or dilated t-tubule lumen without folds; 2, non-circular contoured t-tubule lumen without folds; 3, t-tubules with 2 to 3 layer of folds; or 4, t-tubules with >3 layer of folds) identifies a significant reduction in t-tubule contour in GFPþISO hearts, which is normalized in cBIN1þISO hearts (p < 0.001, chi-square test). Note the Myocardial tissue sections with SERCA2a labeling were imaged with spinning-disc confocal microscopy and compared across groups ( Figure 4C ). In GFPþPBS hearts, a subpopulation of SERCA2a was concentrated to the t-tubule/ junctional sarcoplasmic reticulum (jSR) regions, giving rise to an organized distribution with a major power spectrum peak at 1.8 to 2 mm, corresponding to the full length of a sarcomere. Overexpression of cBIN1 in the cBIN1þPBS hearts further increased SERCA2a signals near t-tubule/jSR. In GFPþISO hearts, intracellular distribution of SERCA2a was disorganized with a significant reduction in peak power density, which was normalized in cBIN1þISO hearts (quantification in Figure 4D ).

was further explored using biochemical sucrose gradient-based fractionation of cardiac microsomes (21) . As indicated in Supplemental Figure Figure 6A ). Myocardial tissue immunofluorescent labeling of Cav1.2 channels reveals that channel density along t-tubules is significantly increased only in cBIN1-expressing hearts, but not the other BIN1 isoforms (Supplemental Figure 6B , quantification in 6D). Immunofluorescent imaging reveals that exogenous cBIN1 introduced by AAV9 organizes SERCA2a distribution (Supplemental Figure 6C , quantification in Supplemental Figure   6E ), consistent with the data from Table 2 ). In all animals, post-ISO cardiac output is significantly increased from its level at baseline, a result from the ISO-induced increase in HR (Supplemental Table 2 ).

However, only cBIN1 hearts also have an improved systolic function, normalized E/e', increased stroke volume, and further increased cardiac output when compared with post-ISO GFP hearts ( Figures 7E to 7H) .

Of note, a partial cBIN1-like effect occurs in mice pretreated with BIN1þ17, which significantly reduces survival rates were included in Figure 8C . 

These data indicate that exogenous cBIN1 reduces as mean AE SEM. Two-way ANOVA was used followed by Fisher LSD test for multiple comparison. *p < 0.05, **p < 0.01, and ***p < 0.001 vs. baseline; #p < 0.05, ##p < 0.01, and ###p < 0.001 vs. the GFP group at 4 weeks post-ISO. Abbreviations as in Figure 1 . WT ¼ wild type; other abbreviations as in Figure 1 . Exogenous cBIN1

hypertrophy to dilated cardiomyopathy and HF in TAC mice.

The mechanism of improvement in cardiac inotropic function by cBIN1 is linked to its known effect in organizing t-tubule microdomains required for dyad organization and efficient EC coupling. cBIN1

creates t-tubule microfolds to organize a slow diffusion zone trapping extracellular t-tubule lumen ions, attracts LTCCs forward trafficking to t-tubules (13), clusters LTCCs that are already delivered to cell surface (39) , and recruits RyRs to couple with LTCCs at dyads (14) . Here we confirm in vivo that exogenous cBIN1, rather than any other BIN1 isoform, increases Figure 6 ). This is consistent with the partial in vivo protective effects from domains to regulate all aspects of calcium handling, cBIN1 produces a positive feedforward mechanism for efficient intracellular beat-to-beat calcium cycling. In future studies it will be interesting to identify whether exogenous cBIN1 alters b-AR expression, intracellular distribution, and functional regulation following chronic sympathetic activation.

We found that over-expression of exogenous cBIN1 is protective in mouse hearts subjected to chronic b-AR suppress NLRP3-mediated neuroinflammation in the hippocampus (22, 23) . However, the relationship between NLRP3 and estrogen in ACVD has not been elucidated.

Several studies strongly suggest that the key differences in the immune-inflammatory processes and resulting inflammatory infiltrate between men and women with ACVD may be driven by sex hormones (24) . Current dogma holds that estrogen has antiinflammatory effects, whereas testosterone promotes inflammation (24) . Indeed, the finding that the incidence of ACVD increases in women as estrogen declines with age and following menopause could be interpreted to indicate a protective role for estrogen in the heart (24) . However, in clinical studies hormone-replacement therapy has failed to decrease ACVD events (25) (26) (27) , emphasizing the complexity of the relationship between vascular biology and estrogen hormones. Indeed, the role of estrogen signaling on expression of IL-1b seems to differ depending on cell type (22, (28) (29) (30) . Similarly, although in general testosterone is believed to promote innate immune cell activation and production of proinflammatory cytokines, there are many conflicting studies (31) .

Many studies now suggest that testosterone inhibits atherosclerosis (32) (33) (34) (35) (36) , and that testosterone deficiency increases the risk of atherosclerotic events (37) (38) (39) Here, we investigated the role of sex in NLRP3

inflammasome-mediated inflammation in atherosclerosis as a first step toward identifying these patient subsets. MICE. All mice were on the C57BL/6 background for these studies. Both male and female Nlrp3 À/À Ldlr À/À and Ldlr À/À mice were used (42) . For bone marrow (BM) transplantation, BM from wild-type, and Nlrp3 -/mice was transplanted into irradiated Ldlr -/mice.

After recovery (6 weeks), chimeric mice were placed on a high-fat diet (HFD) containing 0.15% cholesterol (Harlan Teklad) for 12 weeks (42, 43) .

CASTRATION. One week before HFD, Nlrp3 À/À Ldlr À/À and Ldlr À/À male mice of 8 weeks of age underwent castration (CAS) or sham-surgery. Mice were maintained on inhalation anesthesia (1.5% isoflurane) via nose-cone. Before the start of the surgery, carprofen (5 mg/kg body weight) was administered subcutaneously. The area between the penis and the anus was shaved and cleaned with betadine followed by alcohol to disinfect the scrotum. The area between the penis and the anus was lifted to make a small 1mm horizontal cut. To remove the testes, a small 1mm cut into the inner skin membrane enclosing the testicles was made and the testicles were exteriorized. Testicular arteries were tied off using resorbable Vicryl sutures before removing the testes. Once the testes were removed, the wound was sealed with 2 nylon sutures. Following spontaneous movement, buprenorphine (0.5 mg/kg body weight) and 300 ml of warm saline were administered subcutaneously. In sham-operated mice, both the skin and inner skin membrane between the penis and anus were incised. The testes were drawn out and placed back and the wound was sealed with interrupted nylon sutures.

OVARIECTOMY. One week before HFD, Nlrp3 À/À Ldlr À/À and Ldlr À/À female mice of 8 with Ldlr -/alone, whereas this difference was not significant in males ( Figures 1A and 1B) . DKO females also exhibited 32% less lipid content in aortic root plaque ( Figure 1C ) and 38% less lipid coverage in aortic en face compared with control animals, whereas in males there was no significant difference between DKO and control animals ( Figures 1D and 1E ).

In HFD-fed male mice, NLRP3 deficiency did not affect necrotic core size (Figure 2A ) or macrophage content ( Figure 2C ), whereas these parameters were significantly reduced in NLRP3-deficient females compared with control animals (Figures 2B and 2D) .

Lipid accumulation and cell death within the lesions contribute to activation of inflammatory cells that release proinflammatory and proatherogenic mediators into the serum (46, 47) . We measured IL-1b and IL-18 in the serum and found significantly higher concentrations of IL-1b and IL-18 in female Ldlr À/À mice compared with male mice (Figures 3A and 3B) .

Additionally, peritoneal macrophages were isolated from female and male Ldlr À/À mice after 12 weeks HFD. Cells were pretreated with lipopolysaccharide and then stimulated with NLRP3 activator ATP. Female macrophages secreted significantly more IL-1b, but not tumor necrosis factor-a, compared with male macrophages (Figures 3C and 3D) . (Supplemental Figures 1B and 1C) , suggesting that testosterone may suppress the role of the inflammasome in atherosclerosis development. The blood cholesterol levels and lipid profiles were similar in each group (Table 5) , and so was their weight gain ( Table 4) . We next performed sham-surgery or OVX in female Ldlr -/and Nlrp3 -/-Ldlr -/mice. As expected, sham DKO female mice had smaller aortic root lesions size (Supplemental Figure 1D ), lipid content (Supplemental Figure 1E) , and lipid content in aortic en face (Supplemental Figure 1F ) than sham Ldlr -/mice. However, these differences were lost in the OVX group ( Figures 5D to 5F ) supporting a role for estrogen or progesterone in the effect of the inflammasome. Notably, the blood cholesterol levels and lipid profiles were similar in each group (Table 5) , and so was their weight gain ( Table 4) . Taken together, these data suggest that testosterone suppresses inflammasome-mediated atherosclerosis, whereas estrogen or progesterone promotes inflammasomemediated atherosclerosis development. Therefore, we next measured caspase-1 activity, a read-out of inflammasome activation, in lesion macrophages in aortic roots using FLICA. Plaque macrophages from Ldlr -/male mice had significantly less caspase-1 activity compared with those from Ldlr -/-female mice (Figures 6A and 6B) . Interestingly, CAS significantly increased FLICA positivity in the aortic roots compared with sham-operated males ( Figures 6C and 6D) ; however, OVX did not alter FLICA positivity in aortic roots compared with shamoperated females (Supplemental Figure 2) . These The NLRP3 inflammasome is a multicomponent complex that tightly regulates the maturation and secretion of IL-1b, IL-1a, and IL-18 (54, 55) . Given that the NLRP3 inflammasome regulates multiple cytokines, some researchers have suggested that targeting NLRP3 or caspase-1 may yield better outcomes in inflammatory disease than targeting the IL-1b alone or other IL-1 cytokines in isolation (16) . In this study, we found that Nlrp3 deficiency decreased lesion development and aortic lipid accumulation in HFD-fed

Ldlr À/À female mice, but although the trend was evident in male mice, this protection was not signif- Values are mean AE SEM.

OVX ¼ ovariectomy; other abbreviations as in Table 3 .

Chen et al. Abbreviations as in Tables 1 and 4 . Women have higher death rates following myocardial infarction than men (75, 76) , because of differences in the pathogenesis of atherosclerosis, differential efficacy of drugs (77, 78) , and because vascular assist devices may fit men better than women (79, 80 

IsoLGs are highly reactive lipid dicarbonyl metabolites that constitute a major component of oxidative stress-related injury, and they promote the formation of amyloid.

In a hypertensive murine model, IsoLG adducts and PAOs developed in the atria, along with inducible AF.

IsoLG and PAO accumulation and AF were prevented by the dicarbonyl scavenger 2-HOBA, but not by an inactive analog 4-hydroxybenzylamine.

Mechanically stretched atrial cells generated cytosolic IsoLG adducts and PAOs that were prevented by 2-HOBA.

Natriuretic peptides generated cytotoxic oligomers, a process accelerated by IsoLGs, contributing to atrial PAO formation.

These findings identify a novel pathway during oxidative stress to increase AF susceptibility, and they support the concept of preemptively scavenging reactive downstream mediators as a potential therapeutic approach to prevent AF.

Oxidative damage is implicated in atrial fibrillation (AF), but antioxidants are ineffective therapeutically. The authors tested the hypothesis that highly reactive lipid dicarbonyl metabolites, or isolevuglandins (IsoLGs), are principal drivers of AF during hypertension. In a hypertensive murine model and stretched atriomyocytes, the dicarbonyl Figures 1 and 2) . The (Figures 2B and 2C) .

Small-molecule compounds, exemplified by 2-HOBA, have been identified that react with IsoLGs to pre-emptively scavenge these and closely related dicarbonyl mediators to prevent downstream protein modification (34, 35) . When mice were cotreated with 2-HOBA (starting 3 days before ang II infusion), the formation of IsoLG adducts during hypertension was prevented ( Figures 2B and 2F) . A separate group of hypertensive mice was treated with the related structural analog 4-HOBA, which is a very poor scavenger of IsoLGs (11, 34) . For these animals, IsoLG adduct levels were not significantly different from those seen in mice treated with ang II alone ( Figure 2B) Figures 2E and 2F) , whereas the inactive structural analog 4-HOBA failed to prevent PAO formation ( Figure 2E) . with control mice, the total amount or burden of inducible AF was significantly increased in hypertensive mice ( Figure 4A ). The AF substrate was reversible, with a 95% reduction in total AF burden within 2 weeks after stopping ang II ( Figure 4A) (associated with a 70% reduction in BP (Supplemental Table 1) . Taken together with the results shown in Figure 2 , these findings demonstrate that ang IImediated hypertension promotes the formation of atrial IsoLGs, PAOs, and AF susceptibility, with

IsoLGs playing a critical role in the pathophysiological process. (Figures 5A and 5B) . However, when incubated in the presence of IsoLGs, PAO formation was markedly accelerated. We then examined whether natriuretic peptide oligomers were detrimental to atrial cells. Both ANP and BNP oligomers reduced ATP production in atrial HL-1 cells, indicating cytotoxicity (Figures 5C and 5D ). This effect was most pronounced for oligomers formed during a 1-day incubation, whereas cytotoxicity progressively declined with longer incubation times, most prominently for ANP ( Figure 5C ). This time course is analogous to that observed for amyloid b 1-42 neuronal injury: as monomers coalesce to oligomers and subsequently to less toxic fibrils, PAO formation and associated cytotoxicity develops and then declines in a time-and concentration-dependent manner (17) .

Finally, adjacent sections of hypertensive mouse atria were immunostained for PAOs and either ANP or BNP, with results demonstrating evidence of partial colocalization of natriuretic peptides with atrial oligomers ( Figure 5E ). Taken together, these findings support a role for cytotoxic ANP and BNP oligomers as potential mediators of atrial pathophysiology during hypertension.

As the most common sustained cardiac arrhythmia, AF constitutes a significant public health problem for which optimal medical therapies are lacking. Elucidating early mechanisms that increase AF susceptibility are critical to develop effective preventative and therapeutic strategies. In this study, we identi- (42), histones (43) , and proteasomes (44) . IsoLGs can also adduct to DNA and phosphatidylethanolamines (45, 46) . Tissue

IsoLG adducts are elevated early in animal models of cardiovascular risk factors, including hypertension, obesity, and hyperlipidemia (41), as well as atherosclerosis (13, 14) . They are also increased in other diseases linked to oxidative injury/inflammation, such as chronic ethanol exposure (47) , pulmonary fibrosis (48), Alzheimer's disease (15) , and cancer (49) . To date, IsoLG adducts identified in experimental models have emerged as critical mediators of oxidative injury in the brain during Alzheimer's disease, and in the vasculature during hypertension and atherosclerosis (11, 13, 14, 50) .

Multiple risk factors for developing AF are associated with increased atrial pressure that promotes atrial tension/enlargement, and our results support a critical role for atrial cell stretch in the pathophysiological process. Atrial myocyte stretch triggers a generalized stress response, with activation of immediate early genes, dedifferentiation, activation of hypertrophic signaling cascades, and increased release/production of natriuretic peptides (51, 52) .

Importantly, stretch of ventricular myocytes causes rapid production of superoxide (53) . Similarly, in the present study, we found that atrial myocyte stretch causes IsoLG adduct formation, indicative of atrial ROS production. Prevention of AF susceptibility using a dicarbonyl scavenger is consistent with the concept that stretch-mediated oxidative stress is an early event in generating the AF substrate.

Diseases related to oxidative stress are increasingly linked to proteotoxicity as a contributing mechanism (16, 31, 54) , in particular for neurological and cardiac dysfunction (16, 17, 31) . The generation of atrial PAOs in this model is not unexpected on the basis of several considerations. First, the development of natriuretic peptide-related amyloidosis is almost universal in the aging human atrium (20) (21) (22) . Second, we showed that IsoLGs markedly accelerate the oligomerization of ANP and BNP in vitro and in cells, yielding cytotoxic oligomers, as occurs with amyloid b 1-42 (18, 19) . (Figure 1) is key to FIGURE 6 In Response to Hypertension, Oxidative Stress-Mediated IsoLGs Promote AF Susceptibility Hypertension and atrial cell stretch, as well as the rapid activation of atrial cells, causes oxidative stress and formation of highly reactive IsoLGs, that rapidly adduct and crosslink cellular proteins and other macromolecules. The generation of dysfunctional adducted proteins and protein oligomers promote atrial myocyte dysfunction to increase AF susceptibility. Abbreviations as in Figures 1 and 4 . Finally, although our data demonstrated a reduction in cytotoxicity with longer peptide incubation times for ANP supporting PAOs as the cytotoxic moiety, this was not observed for BNP. Nonetheless, these experiments were performed solely to assess oligomer cytotoxicity, rather than the kinetics of PAO/amyloid formation for the natriuretic peptides. whereby oxidative stress increases AF susceptibility is not known. This paper identifies a novel molecular pathway by which highly reactive lipid dicarbonyl metabolites constituting a major component of oxidative stress-related injury are mechanistically linked to AF susceptibility during hypertension, a disease also linked to oxidative stress. Our findings also define a novel potential mechanism whereby oxidative stress promotes amyloid formation in the atria.

TRANSLATIONAL OUTLOOK: These findings identify a novel pathway during oxidative stress to increase AF susceptibility, and they support the concept of pre-emptively scavenging reactive downstream mediators, rather than targeting generation of reactive oxidative species per se, as a potential therapeutic approach to prevent AF. The scavenger 2-HOBA has been well-tolerated in initial Phase 1 clinical trials, and a Phase 2 trial will start within the next few months to examine its efficacy to prevent AF. 

The bioresorption process of the Absorb BVS has been directly characterized only in a normal swine model and indirectly (by imaging surrogates) in clinical studies.

Using multimodality imaging and histology, this study indicates that in a diseased animal model, the resorption and integration of BVS into the arterial wall is not affected by the presence of untreated hyperlipidemia and atherosclerosis progression.

Imaging and histology suggest that BVS degradation progresses similarly in the presence of atherosclerosis compared with earlier data from nonatherosclerotic arteries. However, BVS is not immune to the development of neoatherosclerosis. The study flowchart is shown in Figure 1 . Figure 1 . . There was no difference in the percent plaque area stenosis between the 2 devices at any of the studied time points ( Figure 2 ). Table 2 , compared to 1-year values, the lumen area remained stable in BVS at 4 years but significantly decreased in EES. The patency ratio of BVS-treated vessels appeared stable between 2 and 4 years but dropped in the EES-treated vessels at 4 years ( Figure 2 ).

OCT ANALYSIS. In all animals, the scaffold struts were no longer discernible along the length of the implanted segments by OCT at 4 years ( Figure 3) . The strut count and its optical appearance changed over time: the recognizable struts were decreased over time, with 95% of preserved box appearance at 1 year, 17% at 2 years, and 7% at 3 years; at 4 years, the struts were not discernible in any implanted segments ( Figure 4) . The overall OCT findings are summarized in Figure 5 , top panels. In addition, relative OCT parameter differences from years 1 to 2, 1 to 3, and 1 to 4 for However, late discontinuities are part of the normal Several limitations were present in the current study.

First, EES was implanted in larger vessels due to stent size availability, but this was offset by normalizing the results to the stent/scaffold size, and efforts were made to keep the arterial injury consistent, irrespective of anatomic location and device type by rigorous control of stent-toartery ratio. Second, the sample size is modest in Future studies are required to clarify how SGLT2 inhibitors exert their impressive cardiovascular effects, which will allow for a more specific targeting of heart failure therapy.

Recent clinical trials have shown that sodium glucose co-transport 2 (SGLT2) inhibitors have dramatic beneficial cardiovascular outcomes. These include a reduced incidence of cardiovascular death and heart failure hospitalization in people with and without diabetes, and those with and without prevalent heart failure. The actual mechanism(s) responsible for these beneficial effects are not completely clear. Several potential theses have been proposed to explain the cardioprotective effects of SGLT2 inhibition, which include diuresis/natriuresis, blood pressure reduction, erythropoiesis, improved cardiac energy metabolism, inflammation reduction, inhibition of the sympathetic nervous system, prevention of adverse cardiac remodeling, prevention of ischemia/reperfusion injury, inhibition of the Na þ /H þ -exchanger, inhibition of SGLT1, reduction in hyperuricemia, increasing autophagy and lysosomal degradation, decreasing epicardial fat mass, increasing erythropoietin levels, increasing circulating pro-vascular progenitor cells, decreasing oxidative stress, and improving vascular function. The strengths and weaknesses of these proposed mechanisms are reviewed in an effort to try to synthesize and prioritize the mechanisms as they relate to clinical event reduction. expected to benefit the failing heart. However, the blood pressure-lowering effects of SGLT2 inhibition are modest and are unlikely to completely explain the beneficial cardiovascular and kidney effects of these drugs. In addition, blood pressure lowering would be anticipated to have a greater effect on stroke rates compared with other cardiovascular outcomes, which was not observed in the EMPA-REG OUTCOME trial (8) . Finally, in the DAPA-HF trial, the reductions in blood pressure were quite modest and unlikely to be related to the large reduction in failure events (6) . When compared with a loop diuretic (bumetanide), dapagliflozin was associated with more reduction in interstitial versus intravascular volume (24) . It has therefore been speculated that SGLT2 inhibition may afford a differential effect in regulating interstitial fluid (vs. intravascular volume), which may limit the reflex neurohumoral stimulation that occurs in response to intravascular volume contraction with traditional diuretics.

IMPROVED CARDIAC ENERGY METABOLISM. Dramatic changes in energy metabolism occur in the failing heart. As heart failure progresses, a continual decline in mitochondrial oxidative metabolism occurs, and the heart becomes more reliant on glycolysis as a source of energy (25) . Mitochondrial glucose oxidation decreases in the failing heart (26-28),

leading to a decrease in energy production and a fuelstarved heart (29) . The uncoupling between glycolysis and glucose oxidation in the failing heart also leads to increased proton production that leads to a decrease in cardiac efficiency (cardiac work / O 2 consumed) (25) (26) (27) (28) . This decrease in cardiac efficiency is not confined to patients with heart failure and reduced ejection fraction, but also occurs in patients with heart failure and preserved ejection fraction with left ventricular (LV) hypertrophy who also have a reduced LV mechanical efficiency (30) .

It has been proposed that the beneficial effects of SGLT2 inhibitors in heart failure can occur by improving cardiac energetics and improving cardiac efficiency. SGLT2 inhibitors increase circulating ketone levels, secondary to mobilizing adipose tissue fatty acids, which are then used by the liver for ketogenesis (31) (32) (33) . Circulating ketone levels can increase following SGLT2 inhibitor treatment even in the absence of diabetes (33) . These ketones have been proposed to improve cardiac energetics and cardiac efficiency by being a "thrifty" fuel for the heart (34, 35) . However, we have shown that ketones are not a more efficient source of fuel for the heart, but they are an additional source of fuel for the failing heart (36, 37) . The failing heart is "energy starved," due primarily to a decrease in mitochondrial oxidative metabolism (25, 29) . Ketone oxidation is increased in the failing heart, which has been proposed to be an adaptive metabolic process (37) (38) (39) (40) . Increasing plasma ketone levels in the blood due to SGLT2 inhibition does increase cardiac ketone oxidation rates and therefore improves energy supply to the "starving" failing heart (41) . In diabetic cardiomyopathic mice, empagliflozin-induced increases in cardiac ketone oxidation provide an additional source of fuel for the heart, which is associated with an improvement in cardiac performance ( Figure 2 ) (41). In support of this, Santos-Gallego et al. (42) have shown that empagliflozin can decrease adverse remodeling and heart failure in a porcine model of heart failure, by improving cardiac energetics. It has also been shown that SGLT2 inhibitors can improve mitochondrial respiratory function in diabetic rats (43) , which also may contribute to improving energy production in the heart. These changes in mitochondrial respiration have been proposed to be partially mediated due to favorable alterations in energy supply to the heart.

Ketone infusions into patients with heart failure is also associated with an improvement in contractile performance (44) . Of interest, this ketone-induced improvement in contractile performance is also not associated with an increase in cardiac efficiency. This makes sense, as the oxidation of ketones, compared with the oxidation of glucose, are not a more efficient source of energy. As a result, some of the beneficial effects of SGLT2 inhibition in heart failure may occur secondary to increasing fuel supply to the failing heart, as opposed to supplying the heart with a more efficient source of fuel. Additionally, the increase in cardiac ketone oxidation in the failing heart is not associated with a decrease in either glucose or fatty canagliflozin (49), and dapagliflozin (50) have been shown to attenuate or ameliorate the inflammatory profile in patients with diabetes. This decrease in anti-inflammatory properties of SGLT2 inhibitors has the potential to decrease molecular processes related to inflammation, such as extracellular matrix turnover and fibrosis (51) . In support of this, dapagliflozin has been shown to have marked antifibrotic effects in the post-infarct rat heart by suppressing collagen synthesis (51) . Empagliflozin also significantly attenuates cell-mediated extracellular matrix collagen remodeling (52) . Adverse cardiac remodeling is an important suggest that even short-term exposure to SGLT2 inhibitors can promote cardiac reverse remodeling ( Figure 3) . Inhibition of the mammalian target of rapamycin pathway, a major pathway involved in cardiac hypertrophy, by SGLT2 inhibition may also be involved (76) . Prevention of adverse remodeling with SGLT2 inhibition is also associated with a decreased fibrosis (52, 78) , which may in part be mediated by the anti-inflammatory actions of SGLT2 inhibition (see reduction in inflammation discussion The Na þ /H þ exchanger is increased in the failing heart and can lead to Na þ and Ca 2þ overload in the heart (reviewed by Wakabayashi et al. [80] ). Inhibition of the Na þ /H þ exchanger has also been demonstrated to protect the heart in several experimental models of heart failure (see Wakabayashi et al. [80] for review).

Inhibition of the Na þ /H þ exchanger has been proposed to explain the beneficial effects of SGLT2 inhibitors in heart failure (81) (82) (83) (84) (85) . The cardiac Na þ /H þ exchanger is inhibited by SGLT2 inhibitors, which can lower myocardial Na þ levels (81) . However, it is not clear whether direct inhibition of the cardiac Na þ /H þ exchanger occurs at clinically relevant concentrations of SGLT2 inhibitors. In addition, the development of Na þ /H þ exchanger inhibitors has not been shown to be beneficial in the clinical setting of heart failure (85) . Therefore, it is not clear whether some of the beneficial effects of SGLT2 inhibition in the setting of heart failure may occur secondary to direct inhibition of the cardiac Na þ /H þ exchanger.

INHIBITING SGLT1. Although the heart does not express SGLT2, it does express some SGLT1. Inhibition of SGLT1 in the heart has the potential to decrease myocardial Na þ and glucose uptake and decrease hyperglycemia-induced generation of reactive oxygen species (ROS) (86) . However, whereas some of the SGLT2 inhibitors will decrease SGLT1, such as canagliflozin, the concentration necessary to inhibit SGLT1 is much higher than the plasma concentrations seen with the clinical use of SGLT2 inhibitors. In addition, the use of dual inhibitors of SGLT2 and SGLT1 can exacerbate cardiac dysfunction post-myocardial infarction in rats (87) . As a result, it is unlikely that the beneficial effects of SGLT2 inhibitors can be explained by any secondary effect on SGLT1 inhibition.

HYPERURICEMIA. SGLT2 inhibitors decrease plasma uric acid, which adversely affects the prognosis of heart failure (88) . Small reductions in uric acid levels have been seen with SGLT2 inhibitor treatment (89) . This may be attributed to the increased glycosuria in the proximal tubules due to SGLT2 inhibition, which stimulates uric acid secretion (90) . However, whether a reduction in hyperuricemia by SGLT2 inhibition is a marker or plays a causal role remains unknown.

DEGRADATION. Cardiac autophagy and lysosomal degradation can be impaired in diabetes and heart failure (77, 91) . By driving catabolic rates due to constant glycosuria, it has been proposed that SGLT2 inhibition can promote autophagy and lysosomal degradation, thereby improving mitochondrial morphology and function (77) . An SGLT2-mediated inhibition of mammalian target of rapamycin may also stimulate autophagy and lysosomal degradation, leading to the enhanced degradation of dysfunctional organelles. It therefore cannot be ruled out that some of the benefit of SGLT2 inhibition in heart failure may be secondary to their effects on stimulating autophagy. when a known effective treatment exists, new treatments must be tested against it except when "it is necessary to determine the efficacy or safety of an intervention and the patients who receive any intervention less effective than the best proven one, placebo, or no intervention will not be subject to additional risks of serious or irreversible harm as a result of not receiving the best proven intervention" (6) . Could one really say that withholding remdesivir after it was found to shorten time to recovery-the primary trial outcome participants were told about in the consent form-would not place patients who were hospitalized with COVID-19 at an additional risk of "serious or irreversible harm as a result of not receiving the best proven intervention?" It is also worth noting that ACCT-1 was not designed nor powered for a mortality outcome. Moreover, during a period of pandemic, it is fair to assume that most hospitalized patients want to try something that is effective rather than continuing on placebo.

Mozersky et al. as we pursue a goal such as providing acutely ill patients with a proven intervention (7) . That is to say, even if we prioritize the protection of study participants and society's need for an initial proven intervention, we should support efforts to determine whether remdesivir reduces mortality to whatever extent is possible after dropping placebo controls.

Conceivably this can be done with remdesivir in the context of nonrandomized clinical trials that use propensity matching of treated patients and untreated case control subjects. Admittedly, the results will not be as definitive as an RCT and may represent a lost opportunity; however, this may be the type of scientific compromise that is both reasonable and required in the context of the public health crisis that we are currently facing and will likely have to face again in the future. Many aspects of evidence-based medicine are based on less than perfect evidence, and we must never forget that the participants enrolling in a clinical trial during a deadly pandemic are first and foremost patients who trust their physicians to do what is best for them. As always, we welcome your thoughts on the ACCT-1 trial, either through social media (#JACC:BTS) or by e-mail (jaccbts@acc.org).

The partial results of the ACCT-1 trial were published online (8) 

Clonal hematopoiesis and atherosclerosis

CRISPR-mediated gene editing to assess the roles of Tet2 and Dnmt3a in clonal hematopoiesis and cardiovascular disease

Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1beta/NLRP3 inflammasome

Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice

Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease

Atherosclerosis and sex hormones: current concepts

Hormone therapy and in-hospital survival after myocardial infarction in postmenopausal women

Integrating topics of sex and gender into medical curricula-lessons from the international community

Sex and gender differences in cardiovascular drug therapy

Gender differences during mechanical circulatory support

Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study

Oxidant and inflammatory mechanisms and targeted therapy in atrial fibrillation: an update

Inflammation in newonset atrial fibrillation after cardiac surgery: a systematic review

Markers of oxidative stress after ablation of atrial fibrillation are associated with inflammation, delivered radiofrequency energy and early recurrence of atrial fibrillation

Time course of inflammation, myocardial injury, and prothrombotic response after radiofrequency catheter ablation for atrial fibrillation

Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study

Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study

Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention

Identification of extremely reactive g-ketoaldehydes (isolevuglandins) as products of the isoprostane pathway and characterization of their lysyl protein adducts

Modification of proteins by isoketal-containing oxidized phospholipids

DC isoketal-modified proteins activate T cells and promote hypertension

Highly-reactive isolevuglandins promote atrial fibrillation susceptibility in obesity (abstr)

Scavenging dicarbonyls with 5 0 -O-pentyl-pyridoxamine improves insulin sensitivity and reduces atherosclerosis through modulating inflammatory Ly6Chi monocytosis and macrophage polarization

Scavenging of reactive dicarbonyls with 2-hydroxybenzylamine reduces atherosclerosis in hypercholesterolemic LdlrÀ/À mice

Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins

Prostaglandin H2 (PGH 2 ) accelerates formation of amyloid b1-42 oligomers

Effect of aldehydes derived from oxidative deamination and oxidative stress on beta-amyloid aggregation; pathological implications to Alzheimer's disease

Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation

Patterns of isolated atrial amyloid: a study of 100 hearts on autopsy

Amyloid deposition as a cause of atrial remodelling in persistent valvular atrial fibrillation

Hypertension is associated with preamyloid oligomers in human atrium: a missing link in atrial pathophysiology?

Reactive g-ketoaldehydes promote protein misfolding and preamyloid oligomer formation in rapidly-activated atrial cells

Inflammation, immunity, and hypertension

Rapid stimulation causes electrical remodeling in cultured atrial myocytes

Inflammation and mechanical stretch promote aortic stiffening in hypertension through activation of p38 mitogen-activated protein kinase

Characterization of the lysyl adducts of prostaglandin H-synthases that are derived from oxygenation of arachidonic acid

Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis

Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis

Quantitative imaging of preamyloid oligomers, a novel structural abnormality, in human atrial samples

Levuglandin forms adducts with histone H4 in a cyclooxygenase-2-dependent manner, altering its interaction with DNA

Effects of reactive g-ketoaldehydes formed by the isoprostane pathway (isoketals) and cyclooxygenase pathway (levuglandins) on proteasome function

Characterization of covalent adducts of nucleosides and DNA formed by reaction with levuglandin

Isoketals form cytotoxic phosphatidylethanolamine adducts in cells

Formation of g-ketoaldehyde-protein adducts during ethanolinduced liver injury in mice

Accumulation of isolevuglandin-modified protein in normal and fibrotic lung

Isolevuglandins as a gauge of lipid peroxidation in human tumors

Treatment with a g-ketoaldehyde scavenger prevents working memory deficits in hApoE4 mice

Mechanisms of atrial structural changes caused by stretch occurring before and during early atrial fibrillation

Cyclical stretch induces structural changes in atrial myocytes

X-ROS signaling: rapid mechano-chemo transduction in heart

Oxidative stress and inflammation in atrial fibrillation: role in pathogenesis and potential as a therapeutic target

Antioxidants for prevention of atrial fibrillation: a potentially useful future therapeutic approach? A review of the literature and meta-analysis

Reactive g-ketoaldehydes promote protein misfolding and preamyloid oligomer formation in rapidly-activated atrial cells

Hypertension is associated with preamyloid oligomers in human atrium: a missing link in atrial pathophysiology?

Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment

Inhibition of experimental neointimal hyperplasia and neoatherosclerosis by local, stent-mediated delivery of everolimus

Lumen gain and restoration of pulsatility after implantation of a bioresorbable vascular scaffold in porcine coronary arteries

Arterial remodeling after bioresorbable scaffolds and metallic stents

Echogenicity as a surrogate for bioresorbable everolimus-eluting scaffold degradation: analysis at 1-, 3-, 6-, 12-18, 24-, 30-, 36-and 42-month follow-up in a porcine model

Very late thrombosis after bioresorbable scaffolds. Cause for concern?

In-stent neoatherosclerosis: a final common pathway of late stent failure

Neoatherosclerosis after drug-eluting stent implantation: a novel clinical and therapeutic challenge

Mechanisms of very late bioresorbable scaffold thrombosis: the INVEST registry

Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent in routine PCI: three-year clinical outcomes from the AIDA trial

Three-year outcomes with the Absorb bioresorbable scaffold: individual-patient-data meta-analysis from the ABSORB randomized trials

Mechanisms of very late bioresorbable scaffold thrombosis: the INVEST registry

Impact of coronary atherosclerosis on bioresorbable vascular scaffold resorption and vessel wall integration

Possible mechanical causes of scaffold thrombosis: insights from case reports with intracoronary imaging

Randomized comparison between everolimus-eluting bioresorbable scaffold and metallic stent: multimodality imaging through 3 years

The war against heart failure: the Lancet lecture

Management of comorbid diabetes mellitus and worsening heart failure

Diabetes mellitus, microalbuminuria, and subclinical cardiac disease: identification and monitoring of individuals at risk of heart failure

Cardiovascular disease and risk management: standards of medical care in diabetes-2019

Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences

for the DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction

The DAP-HF trial: a momentous victory in the war against heart failure

for the EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes

for the CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes

for CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

for the DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

Pump, pipes, and filter: do SGLT2 inhibitors cover it all?

SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-ofthe-art review

Cardiovascular protection by sodium glucose cotransporter 2 inhibitors: potential mechanisms

Use of sodium-glucose co-transport inhibitors in patients with and without type 2 diabetes: implication for incident and prevalent heart failure

SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses

SGLT-2 inhibitors in heart failure: current management, unmet needs, and therapeutic prospects

Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients

Renal handling of ketones in response to sodiumglucose cotransporter 2 inhibition in patients with type 2 diabetes

Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study

Twentyfour-hour ambulatory blood pressure reduction patterns after renal denervation in the SPYRAL HTN-OFF MED Trial

Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis

Myocardial fatty acid metabolism in health and disease

Cardiac insulin-resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy

Malonyl CoA decarboxylase inhibition improves cardiac function post-myocardial infarction

Agonistinduced hypertrophy and diastolic dysfunction are associated with selective reduction in glucose oxidation: a metabolic contribution to heart failure with normal ejection fraction

The failing heart-an engine out of fuel

Energetics in heart failure with preserved ejection fraction

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients

Shift to fatty substrates utilization in response to sodiumglucose co-transporter-2 inhibition in nondiabetic subjects and type 2 diabetic patients

Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis

CV Protection in the EMPA-REG OUTCOME trial: a "thrifty substrate" hypothesis

Empagliflozin's fuel hypothesis: not so soon

Increased ketone body oxidation provides additional energy for the failing heart without improving cardiac efficiency

Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure

The failing heart relies on ketone bodies as a fuel

The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense

Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors

Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics

Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats

Cardiovascular effects of treatment with the ketone body 3-hydroxybutyrate in chronic heart failure patients

Chronic heart failure and inflammation: what do we really know?

Minireview: are SGLT2 inhibitors heart savers in diabetes? Heart Fail Rev

The importance of NLRP3 inflammasome in heart failure

Empagliflozin protects against diet-induced NLRP-3 inflammasome activation and lipid accumulation

Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice

Senescent T cells predict the development of hyperglycemia in humans

Dapagliflozin attenuates Naþ/Hþexchanger-1 in cardiofibroblasts via AMPK activation

Empagliflozin blunts worsening cardiac dysfunction associated with reduced NLRP3 (nucleotidebinding domain-like receptor protein 3) inflammasome activation in heart failure

The ketone metabolite b-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease

The association between the dosage of SGLT2 inhibitor and weight reduction in type 2 diabetes patients: a metaanalysis

Emerging role of SGLT-2 inhibitors for the treatment of obesity

Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms

Revisiting the links between glycaemia, diabetes and cardiovascular disease

Evaluating the effects of canagliflozin on cardiovascular and renal events in patients with type 2 diabetes and chronic kidney disease according to baseline HbA1c, including those with HbA1c <7%: results from the CREDENCE trial

Empagliflozin improves diastolic function in a nondiabetic rodent model of heart failure with preserved ejection fraction

Dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, acutely reduces energy expenditure in BAT via neural signals in mice

Arterial pressure lability is improved by sodiumglucose cotransporter 2 inhibitor in streptozotocin-induced diabetic rats

Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2

Hypovolemia and neurovascular control during orthostatic stress

The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus

A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity

Dapagliflozin attenuates cardiac remodeling in mice model of cardiac pressure overload

Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME trial?

SGLT2 inhibitors: clinical benefits by restoration of normal diurnal metabolism

The sodiumglucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats

SGLT2 inhibitor, canagliflozin, attenuates myocardial infarction in the diabetic and nondiabetic heart

Regulation of the cardiac Na⁺/H⁺ exchanger in health and disease

Empagliflozin decreases myocardial cytoplasmic Na þ through inhibition of the cardiac Na þ /H þ exchanger in rats and rabbits

Direct cardiac actions of sodium glucose cotransporter 2 inhibitors target pathogenic mechanisms underlying heart failure in diabetic patients

Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis

Unraveling the molecular mechanism of action of empagliflozin in heart failure with reduced ejection fraction with or without diabetes

for the EXPEDITION Study Investigators. Sodiumhydrogen exchange inhibition by cariporide to reduce the risk of ischemic cardiac events in patients undergoing coronary artery bypass grafting: results of the EXPEDITION study

SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection

Dual inhibition of sodium-glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction

Uric acid predicts clinical outcomes in heart failure: insights regarding the role of xanthine oxidase and uric acid in disease pathophysiology

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial

inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria

The role of autophagy in vascular biology

Statins reduce epicardial adipose tissue attenuation independent of lipid lowering: a potential pleiotropic effect

The effect of dapagliflozin treatment on epicardial adipose tissue volume

Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys

Effect of empagliflozin on erythropoietin levels, iron stores and red blood cell morphology in patients with type 2 diabetes and coronary artery disease

SGLT2 Inhibition with empagliflozin increases circulating provascular progenitor cells in people with type 2 diabetes mellitus

Mitochondrial dysfunction in pathophysiology of heart failure

SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart

Empagliflozin and dapagliflozin reduce ROS generation and restore NO bioavailability in tumor necrosis factor a-stimulated human coronary arterial endothelial cells

Endothelial dysfunction

Heart failure etiology affects peripheral vascular endothelial function after cardiac transplantation

Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: a potential mechanism for inhibition of atherogenesis. Diabetes Vasc

Canagliflozin inhibits interleukin-1b-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinasedependent and -independent mechanisms

COVID-19 clinical trials: a primer for the cardiovascular and cardio-oncology communities

Inside the NIH's controversial decision to stop its big remdesivir study

What makes clinical research ethical

for the PALM Consortium Study Team. A randomized, controlled trial of Ebola virus disease therapeutics

Integrating Clinical Research into Epidemic Response: The Ebola Experience

World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects

Public health ethics: mapping the terrain

Remdesivir for the treatment of Covid-19 -preliminary report

The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more in-The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit